RESUMEN
BACKGROUND: Several medicines have been shown to be effective in treating neuropathic pain, but they can have damaging side effects, therefore people are now trying herbal products to help relieve pain. OBJECTIVE: The aim of the Cochrane Review was to evaluate whether herbal products/preparations have an analgesic effectiveness in neuropathic pain and whether any side effects are associated with their use. METHODS: The population addressed were adults aged ≥18 years, suffering from chronic neuropathic pain. Studies that investigated the effects of herbal products/preparations for the relief of neuropathic pain compared to any or no interventions were included. RESULTS: Included studies did not show that herbal products/preparations have reduced pain intensity of 30% or above and there was no observable reduction in the total pain score. CONCLUSIONS: There is insufficient evidence to suggest that herbal products/preparations have any efficacy in any neuropathic pain conditions. The current evidence is of very low quality resulting in serious uncertainties about the estimates of effect observed.
Asunto(s)
Analgésicos/uso terapéutico , Medicina de Hierbas/métodos , Neuralgia/diagnóstico , Neuralgia/tratamiento farmacológico , Preparaciones de Plantas/uso terapéutico , Adulto , Anciano , Analgésicos/aislamiento & purificación , Femenino , Medicina de Hierbas/tendencias , Humanos , Masculino , Persona de Mediana Edad , Neuralgia/epidemiología , Preparaciones de Plantas/aislamiento & purificaciónRESUMEN
PURPOSE OF REVIEW: Postmastectomy pain syndrome (PMPS) remains poorly defined, although it is applied to chronic neuropathic pain following surgical procedures of the breast, including mastectomy and lumpectomy in breast-conserving surgery. It is characterized by persistent pain affecting the anterior thorax, axilla, and/or medial upper arm following mastectomy or lumpectomy. Though the onset of pain is most likely to occur after surgery, there may also be a new onset of symptoms following adjuvant therapy, including chemotherapy or radiation therapy. RECENT FINDINGS: The underlying pathophysiology is likely multifactorial, although exact mechanisms have yet to be elucidated. In this regard, neuralgia of the intercostobrachial nerve is currently implicated as the most common cause of PMPS. Numerous pharmacological options are available in the treatment of PMPS, including gabapentinoids, tricyclic antidepressants, selective serotonin reuptake inhibitors, NMDA receptor antagonists, and nefopam (a non-opioid, non-steroidal benzoxazocine analgesic). Minimally invasive interventional treatment including injection therapy, regional anesthesia, botulinum toxin, and neuromodulation has been demonstrated to have some beneficial effect. A comprehensive update highlighting current perspectives on the treatment of postmastectomy pain syndrome is presented with emphasis on treatments currently available and newer therapeutics currently being evaluated to alleviate this complex and multifactorial condition.
Asunto(s)
Mastectomía , Neuralgia/terapia , Dolor Postoperatorio/terapia , Inhibidores de la Liberación de Acetilcolina/uso terapéutico , Analgésicos/uso terapéutico , Anestesia de Conducción , Anestésicos Locales/uso terapéutico , Antidepresivos Tricíclicos/uso terapéutico , Brazo , Axila , Toxinas Botulínicas Tipo A/uso terapéutico , Terapia por Estimulación Eléctrica/métodos , Gabapentina/uso terapéutico , Ganglios Espinales , Humanos , Memantina/uso terapéutico , Nefopam/uso terapéutico , Bloqueo Nervioso , Neuralgia/diagnóstico , Neuralgia/epidemiología , Manejo del Dolor , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/epidemiología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Pared Torácica , Puntos DisparadoresRESUMEN
Neuropathic pain remains a significant unmet medical need. Several recommendations have recently been proposed concerning pharmacotherapy, neurostimulation techniques and interventional management, but no comprehensive guideline encompassing all these treatments has yet been issued. We performed a systematic review of pharmacotherapy, neurostimulation, surgery, psychotherapies and other types of therapy for peripheral or central neuropathic pain, based on studies published in peer-reviewed journals before January 2018. The main inclusion criteria were chronic neuropathic pain for at least three months, a randomized controlled methodology, at least three weeks of follow-up, at least 10 patients per group, and a double-blind design for drug therapy. Based on the GRADE system, we provide weak-to-strong recommendations for use and proposal as a first-line treatment for SNRIs (duloxetine and venlafaxine), gabapentin and tricyclic antidepressants and, for topical lidocaine and transcutaneous electrical nerve stimulation specifically for peripheral neuropathic pain; a weak recommendation for use and proposal as a second-line treatment for pregabalin, tramadol, combination therapy (antidepressant combined with gabapentinoids), and for high-concentration capsaicin patches and botulinum toxin A specifically for peripheral neuropathic pain; a weak recommendation for use and proposal as a third-line treatment for high-frequency rTMS of the motor cortex, spinal cord stimulation (failed back surgery syndrome and painful diabetic polyneuropathy) and strong opioids (in the absence of an alternative). Psychotherapy (cognitive behavioral therapy and mindfulness) is recommended as a second-line therapy, as an add-on to other therapies. An algorithm encompassing all the recommended treatments is proposed.
Asunto(s)
Neuralgia/tratamiento farmacológico , Neuralgia/terapia , Manejo del Dolor/métodos , Manejo del Dolor/normas , Guías de Práctica Clínica como Asunto , Analgésicos/uso terapéutico , Analgésicos Opioides/uso terapéutico , Antidepresivos/uso terapéutico , Terapia Cognitivo-Conductual , Terapias Complementarias/métodos , Terapias Complementarias/normas , Terapias Complementarias/estadística & datos numéricos , Francia/epidemiología , Humanos , Atención Plena/métodos , Atención Plena/normas , Neuralgia/epidemiología , Manejo del Dolor/estadística & datos numéricos , Guías de Práctica Clínica como Asunto/normas , Estimulación Magnética TranscranealRESUMEN
BACKGROUND: Childhood trauma has been linked to neuropathic pain in noncancer populations, but its relationship with cancer treatment-related neuropathic pain is unknown. OBJECTIVE: This secondary data analysis of a prospective, longitudinal, observational study aimed to explore the relationship of childhood trauma experience with pain severity, pain interference, and neuropathic symptom severity (NSS) 12 months after surgery in women receiving treatment for stage 0 to III breast cancer. METHODS: Women (N = 44) recruited from a comprehensive cancer center self-reported childhood trauma experience, pain severity, pain interference, NSS, co-occurring symptoms, and pain beliefs via questionnaires. Descriptive statistics were used to describe childhood trauma experience. Linear regression was used to model childhood trauma and other predictors on pain variables 12 months after surgery. RESULTS: Childhood trauma predicted pain severity and pain interference 12 months after surgery (P < .05), as did baseline pain severities and helplessness-pain catastrophizing. Age predicted only NSS. Together, the best models predicted 31.6% to 40.9% of the variance in pain severities at 12 months (P < .001). CONCLUSIONS: Childhood trauma exposure was a significant predictor of pain 12 months after breast cancer surgery and adjuvant treatment. Younger and helplessness-pain catastrophizing women are also at risk. Research is needed to identify preventive neuropathic pain interventions for high-risk women. IMPLICATIONS FOR PRACTICE: Women receiving breast cancer treatment should proactively be assessed for childhood trauma history, possibly by using discreet previsit questionnaires. Childhood trauma survivors may be at high risk for poor pain outcomes and may benefit from tailored pain interventions.
Asunto(s)
Adultos Sobrevivientes de Eventos Adversos Infantiles/estadística & datos numéricos , Neoplasias de la Mama/terapia , Supervivientes de Cáncer/estadística & datos numéricos , Neuralgia/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Estudios Longitudinales , Persona de Mediana Edad , Estudios Prospectivos , Medición de Riesgo , Encuestas y CuestionariosRESUMEN
Neuropathic pain is characterized by abnormal hypersensitivity to stimuli (hyperalgesia) and nociceptive responses to non-noxious stimuli (allodynia). The conditions and the pathophysiological states that determine the onset of neuropathic pain are heterogeneous, such as metabolic disorders, neuropathy caused by viral infections, and autoimmune diseases affecting the central nervous system (CNS). Neuropathic pain in the general population is estimated to have a prevalence ranging between 3% and 17%. Most of the available treatments for neuropathic pain have moderate efficacy and present side effects that limit their use; therefore, other therapeutic approaches are needed for patients. In this article, the current standard of care treatment, the emerging pharmacological approaches from the completed phase III clinical trials, and the preclinical studies on novel promising therapeutic options will be reviewed.
Asunto(s)
Analgésicos/uso terapéutico , Neuralgia/tratamiento farmacológico , Dimensión del Dolor/métodos , Analgésicos/farmacología , Animales , Ensayos Clínicos Fase I como Asunto/métodos , Evaluación Preclínica de Medicamentos/métodos , Predicción , Humanos , Neuralgia/diagnóstico , Neuralgia/epidemiología , Dimensión del Dolor/efectos de los fármacos , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate the variation in long-term opioid use in osteoarthritis (OA) patients according to geography and health care access. METHODS: We designed an observational cohort study among OA patients undergoing total joint replacement (TJR) in the Medicare program (2010 through 2014). The independent variables of interest were the state of residence and health care access, which was quantified at the primary care service area (PCSA) level as categories of number of practicing primary care providers (PCPs) and categories of rheumatologists per 1,000 Medicare beneficiaries. The percentage of OA patients taking long-term opioids (≥90 days in the 360-day period immediately preceding TJR) within each PCSA was the outcome variable in a multilevel, generalized linear regression model, adjusting for case-mix at the PCSA level and for policies, including rigor of prescription drug monitoring programs and legalized medical marijuana, at the state level. RESULTS: A total of 358,121 patients with advanced OA, with a mean age of 74 years, were included from 4,080 PCSAs. The unadjusted mean percentage of long-term opioid users varied widely across states, ranging from 8.9% (Minnesota) to 26.4% (Alabama), and this variation persisted in the adjusted models. Access to PCPs was only modestly associated with rates of long-term opioid use between PCSAs with highest (>8.6) versus lowest (<3.6) concentration of PCPs (adjusted mean difference 1.4% [95% confidence interval 0.8%, 2.0%]), while access to rheumatologists was not associated with long-term opioid use. CONCLUSION: We note a substantial statewide variation in rates of long-term treatment with opioids in OA, which is not fully explained by the differences in access to health care providers, varying case-mix, or state-level policies.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Osteoartritis de la Cadera/terapia , Osteoartritis de la Rodilla/terapia , Anciano , Artritis Reumatoide/epidemiología , Artroplastia de Reemplazo de Cadera , Artroplastia de Reemplazo de Rodilla , Dolor de Espalda/tratamiento farmacológico , Dolor de Espalda/epidemiología , Estudios de Cohortes , Comorbilidad , Femenino , Geografía , Humanos , Masculino , Medicare , Neuralgia/tratamiento farmacológico , Neuralgia/epidemiología , Osteoartritis de la Cadera/epidemiología , Osteoartritis de la Rodilla/epidemiología , Manejo del Dolor , Médicos de Atención Primaria , Reumatólogos , Índice de Severidad de la Enfermedad , Estados Unidos/epidemiologíaRESUMEN
This review illustrates some brief considerations of the medical use of cannabis recently issued in Italy. History and uses of cannabis throughout centuries and different countries are illustrated together with a description of botany and active phytocannabinoids. Then, medical use of cannabis anti-pain treatment for patients resistant to conventional therapies is described in case of chronic neuropathic pain, spasticity, for anticinetosic and antiemetic effect in nausea and vomiting caused by chemotherapy, for appetite stimulating effect in cachexia, anorexia, loss of appetite in cancer patients or patients with AIDS and in anorexia nervosa, hypotensive effect in glaucoma resistant to conventional therapies and for reduction of involuntary body and facial movements in Gilles de la Tourette syndrome. Italian most recent legislation on medical cannabis is detailed with some law proposals, also showing the inconsistent legislation within European Union. Some final considerations of future studies are also reported.
Asunto(s)
Legislación de Medicamentos/tendencias , Marihuana Medicinal/uso terapéutico , Manejo del Dolor/tendencias , Antieméticos/uso terapéutico , Caquexia/tratamiento farmacológico , Caquexia/epidemiología , Europa (Continente)/epidemiología , Humanos , Italia/epidemiología , Espasticidad Muscular/tratamiento farmacológico , Espasticidad Muscular/epidemiología , Náusea/tratamiento farmacológico , Náusea/epidemiología , Neoplasias/tratamiento farmacológico , Neoplasias/epidemiología , Neuralgia/tratamiento farmacológico , Neuralgia/epidemiología , Manejo del Dolor/métodos , Síndrome de Tourette/tratamiento farmacológico , Vómitos/tratamiento farmacológico , Vómitos/epidemiologíaRESUMEN
Neuropathic pain is a subset of chronic pain that is caused by neurons that are damaged or firing aberrantly in the peripheral or central nervous systems. The treatment guidelines for neuropathic pain include antidepressants, calcium channel α2 delta ligands, topical therapy, and opioids as a second-line option. Pharmacotherapy has not been effective in the treatment of neuropathic pain except in the treatment of trigeminal neuralgia with carbamazepine. The inability to properly treat neuropathic pain causes frustration in both the patients and their treating physicians. Venoms, which are classically believed to be causes of pain and death, have peptide components that have been implicated in pain relief. Although some venoms are efficacious and have shown benefits in patients, their side-effect profile precludes their more widespread use. This review identifies and explores the use of venoms in neuropathic pain relief. This treatment can open doors to potential therapeutic targets. We believe that further research into the mechanisms of action of these receptors as well as their functions in nature will provide alternative therapies as well as a window into how they affect neuropathic pain.
Asunto(s)
Analgésicos no Narcóticos/uso terapéutico , Neuralgia/tratamiento farmacológico , Péptidos/uso terapéutico , Toxinas Biológicas/uso terapéutico , Ponzoñas/uso terapéutico , Analgésicos no Narcóticos/aislamiento & purificación , Analgésicos no Narcóticos/farmacología , Animales , Humanos , Neuralgia/diagnóstico , Neuralgia/epidemiología , Manejo del Dolor/métodos , Péptidos/aislamiento & purificación , Péptidos/farmacología , Toxinas Biológicas/aislamiento & purificación , Toxinas Biológicas/farmacología , Ponzoñas/aislamiento & purificación , Ponzoñas/farmacología , omega-Conotoxinas/aislamiento & purificación , omega-Conotoxinas/farmacología , omega-Conotoxinas/uso terapéuticoRESUMEN
BACKGROUND: The management of chronic pain is a complex challenge worldwide. Cannabis-based medicines (CBMs) have proven to be efficient in reducing chronic pain, although the topic remains highly controversial in this field. OBJECTIVES: This study's aim is to conduct a conclusive review and meta-analysis, which incorporates all randomized controlled trials (RCTs) in order to update clinicians' and researchers' knowledge regarding the efficacy and adverse events (AEs) of CBMs for chronic and postoperative pain treatment. STUDY DESIGN: A systematic review and meta-analysis. METHODS: An electronic search was conducted using Medline/Pubmed and Google Scholar with the use of Medical Subject Heading (MeSH) terms on all literature published up to July 2015. A follow-up manual search was conducted and included a complete cross-check of the relevant studies. The included studies were RCTs which compared the analgesic effects of CBMs to placebo. Hedges's g scores were calculated for each of the studies. A study quality assessment was performed utilizing the Jadad scale. A meta-analysis was performed utilizing random-effects models and heterogeneity between studies was statistically computed using I² statistic and tau² test. RESULTS: The results of 43 RCTs (a total of 2,437 patients) were included in this review, of which 24 RCTs (a total of 1,334 patients) were eligible for meta-analysis. This analysis showed limited evidence showing more pain reduction in chronic pain -0.61 (-0.78 to -0.43, P < 0.0001), especially by inhalation -0.93 (-1.51 to -0.35, P = 0.001) compared to placebo. Moreover, even though this review consisted of some RCTs that showed a clinically significant improvement with a decrease of pain scores of 2 points or more, 30% or 50% or more, the majority of the studies did not show an effect. Consequently, although the primary analysis showed that the results were favorable to CBMs over placebo, the clinical significance of these findings is uncertain. The most prominent AEs were related to the central nervous and the gastrointestinal (GI) systems. LIMITATIONS: Publication limitation could have been present due to the inclusion of English-only published studies. Additionally, the included studies were extremely heterogeneous. Only 7 studies reported on the patients' history of prior consumption of CBMs. Furthermore, since cannabinoids are surrounded by considerable controversy in the media and society, cannabinoids have marked effects, so that inadequate blinding of the placebo could constitute an important source of limitation in these types of studies. CONCLUSIONS: The current systematic review suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily for neuropathic pain (NP) patients. Additionally, GI AEs occurred more frequently when CBMs were administered via oral/oromucosal routes than by inhalation.Key words: Cannabis, CBMs, chronic pain, postoperative pain, review, meta-analysis.
Asunto(s)
Dolor Crónico/tratamiento farmacológico , Marihuana Medicinal/uso terapéutico , Manejo del Dolor/métodos , Dolor Postoperatorio/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Cannabidiol/uso terapéutico , Cannabis , Dolor Crónico/diagnóstico , Dolor Crónico/epidemiología , Dronabinol/uso terapéutico , Combinación de Medicamentos , Humanos , Neuralgia/diagnóstico , Neuralgia/tratamiento farmacológico , Neuralgia/epidemiología , Manejo del Dolor/tendencias , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/epidemiología , Resultado del TratamientoRESUMEN
Neuropathic pain is a complex, chronic pain state accompanied by tissue injury and nerve damage. This important health issue constitutes a challenge for the modern medicine worldwide. The management of neuropathic pain remains a major clinical challenge, pertaining to an inadequate understanding of pathophysiological mechanisms of neuropathic pain. Various classes of drugs have been reported effective for the management of neuropathic pain viz. opiates, tricyclic antidepressants, and antiepileptic agents. However, association of adverse effects with these drugs hinders their confident prescription in people with neuropathic pain. Recently, various medicinal plants have been reported effective for the management of neuropathic pain. So, it may be prudent to look beyond synthetic drugs pertaining to their unprecedented pharmacotherapeutic effects with lesser adverse effects. The extensive literature review has been carried out from databases such as Science direct, Scifinder, Wiley online library, PubMed, Research gate, Google scholar and Chemical Abstracts. The list of Traditional Indian Medicinal plants (TIMPs) and isolated compounds have been compiled which have been reported effective as an alternative therapy for the management of neuropathic pain. This helps the researchers to discover some novel therapeutic agents against neuropathic pain.
Asunto(s)
Terapias Complementarias/métodos , Medicina Ayurvédica/métodos , Neuralgia/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Plantas Medicinales , Animales , Terapias Complementarias/tendencias , Humanos , Medicina Ayurvédica/tendencias , Neuralgia/diagnóstico , Neuralgia/epidemiología , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificaciónRESUMEN
Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aß, Aδ and C fibres) and central neurons, and affects 7-10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain owing to increased drug prescriptions and visits to health care providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, progress in the understanding of the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.
Asunto(s)
Neuralgia/complicaciones , Neuralgia/diagnóstico , Manejo del Dolor/métodos , Calidad de Vida/psicología , Aminas/farmacología , Aminas/uso terapéutico , Analgésicos/farmacología , Analgésicos/uso terapéutico , Ácidos Ciclohexanocarboxílicos/farmacología , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Quimioterapia Combinada/métodos , Gabapentina , Humanos , Lidocaína/farmacología , Lidocaína/uso terapéutico , Narcóticos/farmacología , Narcóticos/uso terapéutico , Neoplasias/complicaciones , Neuralgia/epidemiología , Dolor Nociceptivo/complicaciones , Dolor Nociceptivo/diagnóstico , Pregabalina/farmacología , Pregabalina/uso terapéutico , Tramadol/farmacología , Tramadol/uso terapéutico , Estimulación Eléctrica Transcutánea del Nervio/métodos , Estimulación Eléctrica Transcutánea del Nervio/normas , Bloqueadores del Canal de Sodio Activado por Voltaje/farmacología , Bloqueadores del Canal de Sodio Activado por Voltaje/uso terapéutico , Ácido gamma-Aminobutírico/farmacología , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
BACKGROUND: Peripheral neuromodulation is often used as chronic neuropathic pain treatment. Percutaneous electrical nerve stimulation (PENS) is generally utilized with several probes at the same time and repeated treatments. OBJECTIVES: Evaluate the short- and long-term efficacy of a single probe and single shot PENS approach. STUDY DESIGN: Multicenter, prospective, observational study. SETTING: Four Italian pain therapy centers. METHODS: Inclusion criteria were age = 18 and = 80 years, presence of severe peripheral neuropathic pain lasting more than 3 months, localized and refractory to pharmacological therapies. Patients with infection, coagulopathies, psychiatric disorders, pacemakers, or implantable cardiac defibrillators were excluded. PATIENTS: Seventy-six patients (47 women, 29 men), mean age 62 ± 14 years, affected by neuralgia (21 herpes zoster infection, 31 causalgia, 24 postoperative pain) were enrolled in the study. INTERVENTION: After localization of trigger point and/or allodynic/hyperalgesic area, PENS therapy was achieved with a single 21 gauge conductive probe tunneled percutaneously and a neurostimulator device. MEASUREMENT: Numerical Rating Scale (NRS) and Neuropathic Pain Scale (NPS) were assessed at baseline, 60 minutes after PENS, at one week, after one, 3, and 6 months; perceived health outcome was measured with Euroqol-5 dimension (EQ-5D) questionnaire at baseline and at 6 months. Adverse events and patient satisfaction were reported. RESULTS: NRS and NPS decreased significantly after 60 minutes and the reduction remained constant over time at follow-up. EQ-5D increased significantly with respect to the baseline. Two nonclinically significant adverse events (one contralateral dysestesia and one self-resolving hematoma) were observed. LIMITATIONS: Small sample size and non-randomized observational study; high prevalence of post-herpetic and occipital neuralgias. CONCLUSION: PENS therapy produced significant and long-lasting pain relief in chronic peripheral neuropathic pains of different etiology. The present study confirms the feasibility, safety, and repeatability of this minimally invasive technique.
Asunto(s)
Neuralgia/diagnóstico , Neuralgia/terapia , Manejo del Dolor/métodos , Estimulación Eléctrica Transcutánea del Nervio/métodos , Adulto , Anciano , Femenino , Herpes Zóster/diagnóstico , Herpes Zóster/epidemiología , Herpes Zóster/terapia , Humanos , Hiperalgesia/diagnóstico , Hiperalgesia/epidemiología , Hiperalgesia/terapia , Italia/epidemiología , Masculino , Persona de Mediana Edad , Neuralgia/epidemiología , Dimensión del Dolor/métodos , Dolor Postoperatorio/diagnóstico , Dolor Postoperatorio/epidemiología , Dolor Postoperatorio/terapia , Satisfacción del Paciente , Estudios Prospectivos , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
AIM: To evaluate treatment options for neuropathic pain and sensory symptoms resulting from diabetic peripheral neuropathy of the feet. METHODS: The databases PubMed, Embase and Web-of-Science were searched for randomized controlled trials, published in the period from database inception to 2 July 2015, that evaluated treatments for diabetic peripheral neuropathy of the feet with placebo or standard treatment as comparators. Participants in these trials included people with diabetes mellitus and diabetic peripheral neuropathy who were given any treatment for diabetic peripheral neuropathy. Risk of bias was assessed using the Delphi list of criteria. Data from the trials were extracted using standardized data extraction sheets by two authors independently. All analyses were performed using RevMan 5.2. In case of clinical homogeneity, statistical pooling was performed using a random effects model. RESULTS: This review included 27 trials on pharmacological, non-pharmacological and alternative treatments. In the meta-analysis of trials of α-lipoic acid versus placebo, total symptom score was reduced by -2.45 (95% CI -4.52; -0.39) with 600 mg i.v. α-lipoic acid (three trials), and was reduced by -1.95 (95% CI -2.89; -1.01) with 600 mg oral α-lipoic acid (two trials). Significant improvements in diabetic peripheral neuropathy symptoms were found with opioids, botulinum toxin A, mexidol, reflexology and Thai foot massage, but not with micronutrients, neurotrophic peptide ORG 2677 and photon stimulation therapy. CONCLUSION: In this review, we found that α-lipoic acid, opioids, botulinum toxin A, mexidol, reflexology and Thai foot massage had significant beneficial results.
Asunto(s)
Terapias Complementarias/métodos , Pie Diabético/terapia , Neuropatías Diabéticas/terapia , Neuralgia/terapia , Manejo del Dolor/métodos , Terapias Complementarias/estadística & datos numéricos , Pie Diabético/epidemiología , Neuropatías Diabéticas/epidemiología , Humanos , Neuralgia/epidemiología , Manejo del Dolor/estadística & datos numéricos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricosRESUMEN
Objective: The objective of this study was to determine current practices in the Lorraine region in the treatment of neuropathic pain and to assess the challenges faced by general practitioners (GPs). Methods: We conducted a qualitative study by the focus group technique, by constituting a balanced panel of GPs to meet diversification requirements. The number of focus groups was defined to obtain data saturation. The lead author of this study acted as an observer, while a facilitator was responsible for moderating the debate. Analysis of transcripts was performed in two ways: firstly, several readings of the transcripts to highlight the main ideas emerging from these discussions, and secondly, integration of verbatim transcripts in NVivo 10 software to allow complementary computer analysis. Results: The GPs interviewed reported that they prescribed Clonazepam (Rivotril®), Carbamazepine (Tegretol®) and Amitriptyline (Laroxyl®) less often than ten years ago, and Gabapentin (Neurontin®), Pregabalin (Lyrica®), Venlafaxin (Effexor®) and Duloxetine (Cymbalta®) more often than ten years ago. They reported many difficulties in the daily management of these patients, especially concerning the psychological or psychiatric components associated with this pain, comorbidities, iatrogenic effects, the inefficacy of the available molecules, the difficulties of access to a specialist (including pain centres), acceptance of treatment by patients, limiting requirements (restrictive marketing authorisations, withdrawal of certain products ). Conclusion: The treatment of neuropathic pain raises a number of difficulties for GPs, but changes in prescribing habits reflect a constant adaptation of clinical practices.
Asunto(s)
Médicos Generales/estadística & datos numéricos , Neuralgia/terapia , Manejo del Dolor/tendencias , Pautas de la Práctica en Medicina/tendencias , Adulto , Anciano , Aminas/uso terapéutico , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Clorhidrato de Duloxetina/uso terapéutico , Femenino , Gabapentina , Médicos Generales/tendencias , Humanos , Masculino , Persona de Mediana Edad , Neuralgia/epidemiología , Manejo del Dolor/métodos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Pregabalina/uso terapéutico , Encuestas y Cuestionarios , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
BACKGROUND: Increasing evidence supports an analgesic effect of repetitive transcranial magnetic stimulation (rTMS) for neuropathic pain (NP). However, the optimal parameters of rTMS (stimulation frequency and treatment sessions) for achieving long-term analgesic effects remain unknown. This study analyzed the current findings in the literature. OBJECTIVE: The aim of this study was to assess the optimal parameters of rTMS for NP, including the rTMS sessions needed for inducing acute as well as long-term analgesic effects. STUDY DESIGN: A meta-analysis of the analgesic effect of high frequency rTMS (HF- rTMS) for neuropathic patients. SETTING: This meta-analysis examined all studies involving the analgesic efficacy of HF-rTMS for NP. METHODS: PubMed, Embase, and the Cochrane library were searched for clinical studies of rTMS treatment on NP published before December 31, 2014. Crude standardized mean differences (SMD) with 95% confidence interval (CI) were calculated for pain intensity after different treatment sessions (from 1 to 10) and follow-up of one or 2 months after rTMS treatment using random effect models. RESULTS: Twenty-five studies (including 32 trials and 589 patients) were selected for the meta-analysis according to the inclusion and exclusion criteria. All 3 HF-rTMS treatments (5, 10, and 20 Hz) produced pain reduction, while there were no differences between them, with the maximal pain reduction found after one and 5 sessions of rTMS treatment. Further, this significant analgesic effect remained forone month after 5 sessions of rTMS treatment. LIMITATIONS: There are limitations of this meta-analysis. For example, the long-term analgesic effects of different HF-rTMS and low frequency (LF) rTMS sessions, including the single session of rTMS on different NP of varying origins have yet not been evaluated; the full degree of pain relief is still unclear for many rTMS studies. CONCLUSIONS: HF-rTMS stimulation on primary motor cortex is effective in relieving pain in NP patients. Although 5 sessions of rTMS treatment produced a maximal analgesic effect and may be maintained for at least one month, further large-scale and well-controlled trials are needed to determine if this enhanced effect is specific to certain types of NP such as post-stroke related central NP.
Asunto(s)
Dolor Crónico/terapia , Neuralgia/terapia , Manejo del Dolor/métodos , Estimulación Magnética Transcraneal/métodos , Dolor Crónico/diagnóstico , Dolor Crónico/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neuralgia/diagnóstico , Neuralgia/epidemiología , Ensayos Clínicos Controlados Aleatorios como Asunto/métodosRESUMEN
Chronic migraine is a disease that affects 0.5-2.5% of the population, depending on the statistics that are analysed and the definition of chronic migraine that is used. It is extraordinarily disabling, since it does not allow the sufferer to carry out any of their scheduled personal, professional or social activities, and it has a great impact on the patients' quality of life, as measured on disability, quality of life and impact on daily activities scales. Yet, nowadays there are treatments that have proven to be effective in cases of chronic migraine, such as OnabotulinumtoxinA. It is a treatment that is well tolerated and with a high rate of efficacy. Yet it is not only a therapeutic tool, but in the world of headaches it has also opened up the doors to invasive treatments, to the learning of techniques and, in short, to placing headaches in referral units that are usually located in tertiary care hospitals. Furthermore, it has also helped to overcome the idea that patients with headache should be visited exclusively by primary care physicians or general neurologists. This is an opportunity to redefine the field of study and the care for headaches that must be seized. In the future, this is going to be complemented by novel treatments with neurostimulation and probably with monoclonal antibodies against the calcitonin gene-related peptide. A revolution has begun in our knowledge and capacity to act. It is our duty to give it the importance and usage it deserves both for our patients and for us as specialists.
TITLE: Posicionamiento de las unidades de cefalea en el ambito de la neurologia: la importancia de la OnabotulinumtoxinA y otras terapias en el tratamiento de la cefalea.La migraña cronica es una enfermedad que afecta al 0,5-2,5% de la poblacion segun las estadisticas que se analicen y la definicion de migraña cronica que se adopte. Es extraordinariamente incapacitante, ya que no permite realizar las actividades personales, profesionales o sociales programadas, y tiene un gran impacto sobre la calidad de vida de los pacientes, medido en escalas de discapacidad, calidad de vida e impacto en la actividad diaria. Sin embargo, actualmente se dispone de tratamientos que han demostrado eficacia en la migraña cronica, como la OnabotulinumtoxinA. Es un tratamiento bien tolerado y con una tasa de eficacia elevada. Pero no es solo una herramienta terapeutica, sino que ha abierto las puertas en el mundo de la cefalea a la realizacion de tratamientos invasivos, al aprendizaje de tecnicas y, en definitiva, a situar la cefalea en unidades de referencia ubicadas, habitualmente, en hospitales de tercer nivel. Ademas, ha ayudado a eliminar el concepto de que los pacientes con cefalea deben ser atendidos exclusivamente por medicos de atencion primaria o neurologos generales. Esta es una oportunidad que debe aprovecharse para redimensionar el campo del estudio y asistencia de la cefalea. En el futuro, esto va a complementarse con novedosos tratamientos con neuroestimulacion y, probablemente, con anticuerpos monoclonales contra el peptido relacionado con el gen de la calcitonina. Se ha iniciado una revolucion en nuestro conocimiento y capacidad de actuacion. Es nuestro deber darle la importancia y uso que se merecen tanto para nuestros pacientes como para nosotros como especialistas.
Asunto(s)
Inhibidores de la Liberación de Acetilcolina/uso terapéutico , Toxinas Botulínicas Tipo A/uso terapéutico , Trastornos de Cefalalgia/terapia , Unidades Hospitalarias , Neurología/organización & administración , Terapias en Investigación , Anticuerpos Monoclonales/uso terapéutico , Calcitonina/antagonistas & inhibidores , Cefalalgia Histamínica/tratamiento farmacológico , Cefalalgia Histamínica/epidemiología , Cefalalgia Histamínica/prevención & control , Cefalalgia Histamínica/terapia , Terapia por Estimulación Eléctrica , Predicción , Fructosa/análogos & derivados , Fructosa/uso terapéutico , Trastornos de Cefalalgia/tratamiento farmacológico , Trastornos de Cefalalgia/epidemiología , Trastornos de Cefalalgia/prevención & control , Unidades Hospitalarias/provisión & distribución , Humanos , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/epidemiología , Trastornos Migrañosos/prevención & control , Trastornos Migrañosos/terapia , Bloqueo Nervioso , Neuralgia/tratamiento farmacológico , Neuralgia/epidemiología , Neuralgia/prevención & control , Neuralgia/terapia , Prevalencia , Precursores de Proteínas/antagonistas & inhibidores , España/epidemiología , Topiramato , Estados Unidos/epidemiologíaRESUMEN
OBJECTIVE: The aim of this study was to test how the presence of central neuropathic pain (CNP) influences the performance of a motor imagery based Brain Computer Interface (BCI). METHODS: In this electroencephalography (EEG) based study, we tested BCI classification accuracy and analysed event related desynchronisation (ERD) in 3 groups of volunteers during imagined movements of their arms and legs. The groups comprised of nine able-bodied people, ten paraplegic patients with CNP (lower abdomen and legs) and nine paraplegic patients without CNP. We tested two types of classifiers: a 3 channel bipolar montage and classifiers based on common spatial patterns (CSPs), with varying number of channels and CSPs. RESULTS: Paraplegic patients with CNP achieved higher classification accuracy and had stronger ERD than paraplegic patients with no pain for all classifier configurations. Highest 2-class classification accuracy was achieved for CSP classifier covering wider cortical area: 82±7% for patients with CNP, 82±4% for able-bodied and 78±5% for patients with no pain. CONCLUSION: Presence of CNP improves BCI classification accuracy due to stronger and more distinct ERD. SIGNIFICANCE: Results of the study show that CNP is an important confounding factor influencing the performance of motor imagery based BCI based on ERD.
Asunto(s)
Interfaces Cerebro-Computador , Imágenes en Psicoterapia/métodos , Actividad Motora/fisiología , Neuralgia/fisiopatología , Neuralgia/psicología , Paraplejía/fisiopatología , Paraplejía/psicología , Adulto , Mapeo Encefálico , Comorbilidad , Sincronización Cortical/fisiología , Electroencefalografía , Potenciales Evocados/fisiología , Femenino , Pie/inervación , Pie/fisiología , Mano/inervación , Mano/fisiología , Humanos , Masculino , Persona de Mediana Edad , Corteza Motora/fisiología , Neuralgia/epidemiología , Paraplejía/epidemiologíaRESUMEN
Neuropathy is a highly prevalent complication of diabetes that is only likely to increase as the diabetic epidemic continues. Unfortunately, the only disease-modifying treatment is to address the underlying diabetes with enhanced glucose control. In patients with type 1 diabetes, improved glycemic control dramatically reduces the incidence of neuropathy. In contrast, in patients with type 2 diabetes, better glucose control has only a marginal effect on the prevention of neuropathy. However, recognition and treatment of neuropathic pain is also important. An ever expanding number of randomized, controlled clinical trials support multiple medications for the reduction of pain. This includes medications such as calcium channel agonists, tricyclic antidepressants, and selective serotonin/norepinephrine reuptake inhibitors. However, the precise order and combination of these medications remains unclear. Furthermore, several new promising medications are being developed. Overall, the cornerstones of the treatment of diabetic neuropathy are improved glycemic control and initiation of a neuropathic pain medication with high levels of evidence to support its use when pain is present.
Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Neuropatías Diabéticas/terapia , Neuralgia/terapia , Analgésicos Opioides/administración & dosificación , Animales , Capsaicina/administración & dosificación , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/epidemiología , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/epidemiología , Neuropatías Diabéticas/diagnóstico , Neuropatías Diabéticas/epidemiología , Humanos , Neuralgia/diagnóstico , Neuralgia/epidemiologíaRESUMEN
OBJECTIVES: Neuropathic cancer pain (NCP) is a common manifestation of cancer and/or its treatment. Treatment following the WHO analgesic ladder provides relief for the majority of cancer pain patients; however, concern remains that opioids may be less efficacious for neuropathic pain (NP) compared with nociceptive pain, often necessitating the use of higher doses. Adjuvants, such as pregabalin, have shown to be efficacious for the treatment of NP, although data come mostly from noncancer studies. The comparative efficacy and safety of opioids versus adjuvants has not been studied for NCP. The aim of this study was to directly compare pregabalin versus a strong opioid for the treatment of NCP. METHODS: A total of 120 patients, diagnosed with "definite" NCP, were randomized into two groups and received increasing doses of either oral pregabalin or transdermal fentanyl for 28 days. VAS score, patient satisfaction, need for opioid rescue, and adverse events (AEs) were recorded. RESULTS: In the pregabalin group, a significantly higher proportion of patients achieved at least 30% reduction in VAS compared with the fentanyl group (73.3%, 95% CI: 60.3%-83.93 vs. 36.7%, 95% CI: 24.5%-50.1%, P < 0.0001, respectively), while the percentage mean change from baseline was also significantly different [46% (95% CI: 39.5%-52.8%) for pregabalin and 22% (95% CI: 14.9%-29.5%) for fentanyl (P < 0.0001)]. Patient-reported satisfaction was more frequent with pregabalin, while AEs and treatment discontinuations were more frequent in the fentanyl group. DISCUSSION: Prompt use of a neuropathic pain-specific adjuvant, such as pregabalin, in NCP may lead to better control of the neuropathic component, with opioid-sparing effects.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Neoplasias/tratamiento farmacológico , Neuralgia/tratamiento farmacológico , Dimensión del Dolor/métodos , Ácido gamma-Aminobutírico/análogos & derivados , Anciano , Analgésicos Opioides/farmacología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Neuralgia/epidemiología , Dimensión del Dolor/efectos de los fármacos , Pregabalina , Estudios Prospectivos , Resultado del Tratamiento , Ácido gamma-Aminobutírico/farmacología , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
BACKGROUND: Taxanes used in adjuvant therapy for breast cancer are neurotoxic, and thereby being a potential risk factor for persistent pain after breast cancer treatment (PPBCT) and sensory disturbances. The purpose was to compare patients treated with cyclophosphamide, epirubicin and fluorouracil (CEF) and cyclophosphamide and epirubicin + docetaxel (CE + T) in relation to PPBCT, sensory disturbances, peripheral sensory disturbances and functional impairment. MATERIAL AND METHODS: A comparative nationwide cross-sectional questionnaire study on two cohorts treated with CEF respectively CE + T, based on the Danish Breast Cancer Cooperative Groups database. INCLUSION CRITERIA: women treated with chemotherapy as adjuvant treatment for primary breast cancer, age 18-69 years, without recurrence. RESULTS: One thousand two hundred and forty-one patients allocated to CEF in 2005-2006 and 1652 patients allocated to CE + T in 2007-2008 were included. Six hundred and sixty-four (53%) with CEF and 861 (53%) patients with CE + T reported pain. In the multivariate analysis including available risk factors, CE + T did not confer an increased risk of PPBCT, OR 0.95 (95% CI 0.81-1.11), p = 0.52, compared to CEF. Patients treated with CE + T had a lower risk of sensory disturbances in the area of surgery compared with CEF, OR 0.75 (95% CI 0.62-0.90), p = 0.002. More CE + T patients reported peripheral sensory disturbances in the hands, OR 1.56 (95%CI 1.27-1.92), p < 0.0001, and in the feet, OR 2.0 (95% CI 1.66-2.42) p < 0.0001, compared to CEF. There was no difference in functional impairment (p = 0.62). CONCLUSION: Docetaxcel as adjuvant treatment for breast cancer does not increase the risk of PPBCT, sensory disturbances in the surgical area or functional impairment, but increase risk for peripheral sensory disturbances.